Cladribine is a highly effective, recently available treatment in multiple sclerosis.
•
This case report describes a patient with a mild COVID-19 infection during second year treatment with cladribine.
•
Normal immune response with detectable antibodies to SARS-CoV2 three months after the infection.
Abstract
Cladribine is a highly effective, recently available treatment in multiple sclerosis. This case report describes a patient with COVID-19 infection during second year treatment with cladribine. The infection was mild and she was able to mount an adequate immune response with detectable antibodies three months later.